Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trebananib + paclitaxel + carboplatin
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptide-Protein Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Trebananib (AMG 386) is an investigational peptibody (peptide-Fc fusion protein) developed by Amgen that acts as an angiogenesis inhibitor by neutralizing the interaction between angiopoietin 1 and 2 and their receptor, Tie2. In the TRINOVA-3 clinical trial, trebananib was evaluated in combination with the standard chemotherapy doublet of paclitaxel and carboplatin for the first-line treatment of epithelial ovarian, primary peritoneal, or fallopian tube cancer. Paclitaxel is a taxane that stabilizes microtubules to prevent cell division, while carboplatin is a platinum-based agent that causes DNA cross-linking. Although the combination was extensively studied, Amgen discontinued the development of trebananib for ovarian cancer after the TRINOVA program failed to demonstrate a significant overall survival benefit.
- Other names
- trebananib + paclitaxel + carboplatinAMG 386 + paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on trebananib + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trebananib + paclitaxel + carboplatin.